Clinical Trial Update: Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the combination of iparomlimab and tuvonralimab (QL1706) with platinum chemotherapy versus platinum chemotherapy alone …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Triple Negative Breast Cancer Metastatic | Phase 2 | Status: NOT_YET_RECRUITING